F-01
Body composition Analysis
Understand your total fat mass, lean muscle mass and visceral adipose tissue score using validated metrics from a single photo.
VisceFat estimates your visceral adiposity, total body fat and metabolic health indicators using a single photo. No wearables, no expensive scans, privacy first approach. Track your body composition and fat loss longitudinally throughout your weight loss journey.
- Hybrid inference
- On-device first, encrypted fallback
- 60 seconds
- Photos, no hardware
- Encrypted & deleted
- Photo discarded right after calibration
01What you get
One photo, and a clearer picture of what the scale misses.
Built specifically for those on a weight loss journey — including GLP-1 users — to monitor body composition change, fat loss, and progress tracking with advanced AI analysis and medical-grade metrics.
F-02
WHtR Tracking
Waist-to-Height Ratio tracking — a stronger predictor of metabolic risk than BMI alone.
F-03
GLP-1 Progress
Track your VisceFat estimated body composition and reach desired fat loss goals along with your GLP-1 therapy with weekly trend analysis.
F-04
Risk Assessment
Personalised cardiovascular and metabolic risk scoring based on your full health profile.
F-05
Medication and GLP-1 doses
Log GLP-1 and other medication doses with gentle reminders. Mark a dose Taken, Snooze 1 h or Skip straight from the notification or your watch.
F-06
Lab results in plain words
Each lab test shows a plain-language name with the medical term in brackets, and a short line on what the test is.
F-07
3-second food log
One tap logs a light, normal or heavy meal, or a quick item. Calories are optional, and it is free.
F-08
Your watch or band
Resting heart rate, HRV, SpO₂, VO₂ max, sleep stages and smart-scale weight through Apple Health or Health Connect. Daily summaries stay encrypted on your phone.
02The science of visceral fat
The fat you cannot see often matters more than your weight.
The hidden fat around your organs that drives metabolic and cardiovascular risk
The Problem
BMI cannot accurately inform VisceFat estimated body composition or visceral fat. People with normal BMI but elevated adiposity are often overlooked in screening.
VAT + BMI > BMI alone for predicting risk
Body Mass Index (BMI) or weight alone cannot predict your body composition, especially visceral fat. It is hidden, dangerous fat present around your organs. Visceral adiposity or visceral adipose tissue score is the better predictor of metabolic disease. It is completely invisible on a standard scale. Waist circumference or waist to height ratio are recommended by US FDA to estimate total body fat including visceral adipose tissue.
Source: US FDA - Obesity and Overweight: Developing Drugs and Biological Products for Weight ReductionUS FDA guidance recommending waist circumference and waist-to-height ratio as measures to estimate total body fat including visceral adipose tissue.
Abdominal Cross-Section — L4/L5 Level · Healthy vs Elevated VAT
Visceral adipose tissue (VAT, yellow) sits inside the peritoneal boundary · Subcutaneous fat (orange) sits outside muscle wall · Based on CT anatomy at L4–L5
Healthy VAT
Elevated VAT
Skin
Subcutaneous fat
Muscle wall
Peritoneum
Visceral adipose tissue (VAT)
Organs
Interactive cross-section showing visceral fat distribution around organs.
GLP-1 & Muscle Loss
Emerging clinical evidence highlights that GLP-1 receptor agonists may reduce skeletal muscle mass alongside fat, raising concerns about sarcopenic obesity.
Unintended muscle loss for GLP-1 RA users
GLP-1 RAs have transformed the management of obesity. However, emerging clinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating sarcopenic obesity, particularly in older or frail individuals with limited muscular reserves. So while people may reach their target weight loss, they in turn may not understand their target body composition, leading to unintended consequences. BMI or weight alone cannot help one understand their body composition.
Source: Emerging clinical evidence on GLP-1 RA and skeletal muscle outcomesSarcopenic obesity — the coexistence of excess fat and reduced muscle mass — is a growing concern with GLP-1 RA weight loss, particularly in older adults.
0×
Higher cardiovascular risk in adults with elevated VAT versus BMI-only screening alone.Visceral adipose tissue is directly pro-inflammatory - it releases cytokines and free fatty acids directly into the hepatic portal circulation.
Lancet, 2023 Visceral adipose tissue is directly pro-inflammatory - it releases cytokines and free fatty acids directly into the hepatic portal circulation.
0M
Adults with normal weight and are metabolically obese (WtHR < 0.5). Their risk is completely invisible on a standard scale. They are typically not diagnosed of obesity and yet have high risk of diabetes or cardiometabolic complications.This "thin-fat" phenotype is especially prevalent in South Asian and East Asian populations, where body fat is disproportionately visceral.
Lancet Commission This "thin-fat" phenotype is especially prevalent in South Asian and East Asian populations, where body fat is disproportionately visceral.
0B
Adults with BMI > 27 kg/m² living with obesity worldwide. Visceral fat is linked to their health outcomes.WHO projects continued growth in obesity rates, with disproportionate impact in lower-income countries.
WHO, 2024 WHO projects continued growth in obesity rates, with disproportionate impact in lower-income countries.
0
WHtR cut-off above which health associations strengthen across all demographic groups.A WHtR of 0.5 means your waist is half your height - a simple, universal rule that outperforms BMI across ethnicities.
BMJ meta-analysis A WHtR of 0.5 means your waist is half your height - a simple, universal rule that outperforms BMI across ethnicities.
Hidden Risk
People with normal BMI but high waist circumference have elevated mortality risk. Waist-to-height ratio is a better predictor than BMI alone.
Millions Are Misdiagnosed
BMI based definition of obesity can underestimate or overestimate adiposity and risk of obesity related complications. Individuals with normal BMI but elevated central adiposity/visceral fat are often overlooked in screening for obesity - even if their risk of diabetes, hypertension and high cholesterol is similar to those with BMI > 27 kg/m². Individuals with South East Asian, Chinese ethnicities are particularly at high risk of building visceral fat at low BMI. On other hand, athletes with high muscle mass and BMI > 27 kg/m² are wrongly deemed with obesity in spite of their WtHR < 0.5.
Source: Lancet Commission - Definition and diagnostic criteria of clinical obesityThe Lancet Commission's 2024 report redefines clinical obesity diagnosis, emphasizing waist-based measures over BMI alone.
Comorbidity Incidence by Weight/Adiposity Category
Source: NCBI Bookshelf provides peer-reviewed medical literature on obesity comorbidities and metabolic risk factors.Thin Fat Obesity - NCBI Bookshelf (NBK568563) · Kapoor, Endotext 2021
Normal weight, low adiposity
Normal weight, high VAT (thin-fat)
Overweight / Obese (BMI ≥27)
Key finding: People with normal weight but high visceral adipose tissue (amber bars) have nearly identical disease risk to those with overweight/obesity (red bars) - despite appearing "healthy" by BMI alone.
Interactive chart showing comorbidity incidence across weight and adiposity categories.
Our Solution
VisceFat uses AI to convert a guided photo into 3D body shape, providing VAT estimates validated against published research.
One Photo. Research Insight.
VisceFat is an AI-based tool that converts guided photo into 3D shape to estimate visceral adipose tissue, body fat and metabolic risk using waist to height ratio. Validated with published extensive datasets and meta-analyses.
Interactive globe showing global health impact of visceral fat.
03How It Works
About a minute in front of your camera, once a week.
Standardised pose protocol borrowed from photogrammetry — repeatable, auditable, and fast enough to do weekly.
Step 01
Take a photoOne-time setup. Used to anchor the regression model to your anthropometric baseline.
Stand 1.5–2 metres from your camera. Front and side views. 30 seconds total.
Step 02
AI analyses your scanThe in-app pose overlay only accepts the photo once your stance, distance, and lighting meet the required tolerance - ensuring consistent, comparable scans.
Our model estimates visceral fat, WHtR, BMI and metabolic risk from your photos.
Step 03
Track your progressML model returns WC, WHtR, total body fat %, VAT mass, and metabolic risk score with accuracy ranges - all quickly.
See your trend over time. Set scan reminders. Compare before and after.
Step 04
Act on insightsWeekly scans build a longitudinal record. Especially useful alongside GLP-1 medications - track actual VisceFat estimated body composition changes, not just weight.
Personalised nudges and recommendations based on your scan history and health profile.
04VisceFat versus alternatives
Estimates from a photo, built on tens of thousands of DXA scans.
| VisceFat | Smart Scale | Tape measure | DEXA Scan | |
|---|---|---|---|---|
| Visceral fat estimateOnly DEXA and CT directly image VAT. VisceFat estimates it via regression from photo-derived waist measurements. | Estimated | No | Indirect | Direct |
| Time to result | Fast | Slow | ~2 min | 15–30 min |
| Cost per scan | Free in beta | — | — | $80–$250 |
| Equipment needed | Phone camera | Bioimpedance scale | Tape | X-ray suite |
| Stores your photo?VisceFat processes the image in a secure enclave and discards it immediately after metrics are returned. Nothing is retained. | Never | N/A | N/A | Clinic record |
| No hardware required | ✓ | ✗ | Partial | ✗ |
04bYour biometrics
Ranges to guide you, not a diagnosis.
Every scan places your VAT score, body fat, and waist-to-height ratio against clinically-defined bands — not a generic population average.
OptimalModerateElevated
Visceral Adipose Tissue (VAT) Score
0
YOU
0 — Optimal50100 — Elevated
Body Fat Percentage
0.0%
YOU
10% — Lean25%40% — High
Waist-to-Height Ratio
0.00
YOU
0.4 — Healthy0.550.65 — High risk
Tap to see what this range means · Sample scores shown for illustration. Your ranges are calibrated to your demographic profile.
05Privacy by design
Your photo is yours, and it stays that way.
Analysis runs on-device by default. If it can't complete, you're asked first — only with your explicit consent is a photo sent, encrypted in transit (TLS 1.3), analysed, and discarded immediately after metrics are returned.
GDPR
HIPAA*
DPDPA
✓
On-device inference by default — no photo leaves your phone
✓
Server fallback only after your explicit per-scan consent
✓
If used, image bytes are deleted after the response
✓
Only numerical metrics persist on-device
✓
Metrics encrypted at rest (AES-256)
✓
No model training on user images
✓
No third-party advertising trackers
✓
No image stored in cloud or CDN
06Why It Matters
Where fat sits says more than what you weigh.
Visceral fat — the fat surrounding your organs — is strongly linked to heart disease, type 2 diabetes, and metabolic syndrome. It can't be seen or felt, but it can be measured.
Image-based waist circumference correlated with DEXAValidation study comparing AI-derived waist measurements to DEXA scans in 1,250 participants, achieving R² = 0.91 for body-fat percentage estimation.
Image-derived waist measurements compared to DEXA scans in 1,250 participants, showing computer vision can reliably estimate central adiposity without expensive medical equipment.
Kaplan, Nguyen, Lin et al. · NCBI Validation study comparing AI-derived waist measurements to DEXA scans in 1,250 participants, achieving R² = 0.91 for body-fat percentage estimation.
Read studyFDA recommends waist circumference as VAT surrogateFDA guidance recognizes waist circumference as a validated surrogate marker for visceral fat in clinical trials and weight management programs.
US FDA guidance recognises waist circumference as a validated surrogate for visceral fat in obesity research and weight management programs.
FDA · Obesity/Overweight Drug Dev. Guidelines FDA guidance recognizes waist circumference as a validated surrogate marker for visceral fat in clinical trials and weight management programs.
Read studyBMI-based obesity definition underestimates riskThe Lancet Commission recommends waist-based measures over BMI alone for accurate clinical obesity research and metabolic risk assessment.
The Lancet Commission recommends moving beyond BMI to waist-based measures for accurate clinical obesity diagnosis and metabolic risk stratification.
The Lancet Diabetes & Endocrinology, 2024 The Lancet Commission recommends waist-based measures over BMI alone for accurate clinical obesity research and metabolic risk assessment.
Read studyWaist circumference predicts mortality in 650,000 adultsPooled analysis of 650,000 adults showing waist circumference as a strong mortality predictor independent of BMI, with exponential risk increase above 90cm (men) / 80cm (women).
Larger waist circumference predicts earlier death even at normal BMI. Central adiposity is a critical risk factor that BMI alone fails to capture across all demographic groups.
Mayo Clinic Proc. / ScienceDirect Pooled analysis of 650,000 adults showing waist circumference as a strong mortality predictor independent of BMI, with exponential risk increase above 90cm (men) / 80cm (women).
Read study09Research Perspective
Built by people who have watched the scale mislead.
Still unsure why you need to track body fat? Here's what endocrinologists know that scales don't tell you.
"We built VisceFat because the existing tools — smart scales, BMI calculators — miss what actually matters clinically: where fat is distributed, not just how much there is."
Metabolic Health Researcher
15+ years studying metabolic health
The Problem We Solve
People need accessible tools to track body composition. We're making research-backed analysis as easy as taking a photo. Validated against published research on VisceFat estimated body composition estimation and metabolic risk assessment.
The Insight
Years in pharma taught us what matters: accurate data, privacy, and removing barriers to insight.
The Mission
Democratize VisceFat estimated body composition analysis. Everyone deserves to understand their metabolic health.
Research-Driven
Models benchmarked against published imaging studies
08About
Careful science, plainly explained.
Our Origin
After a decade in pharma, we realized the tools powering billion-dollar drug trials never reached patients.
While developing treatments for obesity and diabetes at leading pharmaceutical companies, our founders saw a stark gap: the precise VisceFat estimated body composition analysis that informed clinical decisions was locked behind expensive DEXA scans and research labs.
Research-First Approach
Unlike consumer wellness apps, we built VisceFat on validated methods, transparent methodology, and peer-reviewed science.
Literature-BackedPeer-ReviewedEthics-ReviewedOpen Science
Global Standards
Built with privacy and compliance at the core from day one. We maintain strict adherence to international data protection standards.
GDPR
HIPAA
DPDPA
Lab Heritage
Published in NCBI, Lancet, and FDA guidance
Metrics drawn from published weight-management research
Experience the future of VisceFat estimated body composition tracking
Just Photos. Research-backed insight. No barriers.
Beyond BMI12+ metrics
Zero Photo StoragePrivate
Processing TimeFast
Early AccessLimited
Early Access
Join the waitlist
Be among the first to see beyond the scale.
We're opening access through our research pilots first. Join the waitlist to register your interest and get priority access once a pilot opens.
Analysis Speed
Fast
Body Metrics
12+ Data Points
Validation
Research Based
Free during your pilot
No credit card required
Priority access once a pilot opens
Register Interest
Enter your email to register interest and get priority access once a pilot opens.
Your email is used only for beta access notifications. Unsubscribe anytime.
Secure